Exclusive Summary

• - Patents for API and XR formulation have long expired with no meaningful global barriers, enabling broad distribution now.
• - Addresses high-burden indications: ~50 million people with epilepsy globally and ~5 million new cases/year, ensuring steady demand.
• - Listed on WHO EML and first-line/preferred in guidelines for focal-onset epilepsy and trigeminal neuralgia; XR dosing (BID) improves adherence.
• - FDA-GMP certified and US-registered, with CTD/CPP dossier to accelerate registrations and tender access across many markets.
• - Typically 70–95% cheaper than originators; LMIC tender prices can be under US$5 per patient-month, delivering strong pharmacoeconomic value.